(Q53158682)

Revision as of 22:32, 24 November 2024 by Cewbot (talk | contribs) (‎Changed label, description and/or aliases in en, and other parts: Modify PubMed ID: 21334197 citation data from NCBI, Europe PMC and CrossRef)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

English

Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma

scientific article published on February 18, 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (English)

reason for preferred rank

most precise value

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21334197

24 November 2024

1 reference

based on heuristic

inferred from title

Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography

1 reference

based on heuristic

inferred from title

author name string

Deok-Hwan Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Jung-Joon Min

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Ho-Chun Song

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Yong Yeon Jeong

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Woong-Ki Chung

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Soo-Young Bae

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Jae-Sook Ahn

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Yeo-Kyeoung Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Hee-Seung Bom

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Ik-Joo Chung

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Hyeoung-Joon Kim

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Je-Jung Lee

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21334197

24 November 2024

publication date

18 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

full work available at URL

https://api.elsevier.com/content/article/PII:S0959804911000384?httpAccept=text/xml

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

https://api.elsevier.com/content/article/PII:S0959804911000384?httpAccept=text/plain

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

47

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

1312-1318

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

1

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT

3

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

4

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?

5

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma

6

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

7

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

8

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?

9

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

10

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Revised response criteria for malignant lymphoma

11

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Standards for PET image acquisition and quantitative data analysis

12

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

13

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

14

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

15

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

16

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

17

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease

18

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

19

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

20

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma

22

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

23

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

24

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

25

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

26

1 reference

10.1016/J.EJCA.2010.12.027

https://api.crossref.org/works/10.1016/J.EJCA.2010.12.027

24 November 2024

Identifiers

10.1016/J.EJCA.2010.12.027

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21334197

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53158682&oldid=2279305131"